ArticleCHEST pulmonary2026
Expert Consensus to Explore the Definition and Characterization of Methamphetamine-Associated Pulmonary Arterial Hypertension and Key Treatment Considerations.
Article in CHEST pulmonary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methamphetamine use can result in methamphetamine-associated pulmonary arterial hypertension (Meth-APAH). Compared with idiopathic pulmonary arterial hypertension (PAH), Meth-APAH may have a worse clinical course. Research Question: How can methamphetamine use status be classified and what are the associated treatment considerations for patients with Meth-APAH? Study Design and Methods: US-based experts (N = 12) who manage patients with Meth-APAH were recruited to a double-blinded, modified Delphi panel (2 survey rounds and a virtual consensus meeting). During the survey rounds, panelists answered a range of questions with free-text responses or rating statements. For rating questions, consensus was defined as ≥ 80% of panelists rating their agreement (from 7 to 9) or disagreement (from 1 to 3) using a 9-point Likert scale. Results: The panel was unable to reach consensus on the definition of Meth-APAH. Although there was general agreement that Meth-APAH is a group 1 PAH diagnosis in a patient with a history of methamphetamine use, a number of panelists thought that additional details were needed (eg, duration, cumulative exposure) and these details could not be agreed on. The panel agreed that Meth-APAH is heterogeneous in disease course and physicians should explore the potential of methamphetamine use in all new and existing cases of PAH regardless of the regional prevalence of methamphetamine use. The panel achieved consensus that patients with Meth-APAH should be treated for both PAH and drug addiction. There are no Meth-APAH-specific barriers to double combination therapy (ie, endothelin receptor antagonists, phosphodiesterase 5 inhibitors), but a range of patient and disease factors may influence the choice and route of delivery for other therapies. Interpretation: The characterization of Meth-APAH may help facilitate the identification, treatment, and management of patients with Meth-APAH to improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.